Register to receive a free U.S. Market for Urological Devices report synopsis and brochure

Boston Scientific finalized their $1.6 billion acquisition of the American Medical Systems (AMS) urology portfolio previously owned by Endo Health Solutions. Plus a $50 million bonus will be paid out if certain market milestones are achieved in 2016. This portfolio includes their men’s health division and prostate health businesses. Boston Scientific will integrate the newly purchased products like AMS’s minimally invasive GreenLight XPS and HPS laser therapy systems, the AMS 800 urinary control system and AMS 700 inflatable penile prosthesis, into its existing urology and women’s health business. Boston Scientific Urology and Pelvic Health will continue to invest in gynecological surgical solutions, as well.

“This is an exciting day as we join forces and welcome the AMS men’s health and prostate health teams to Boston Scientific. Together, we create a business with nearly $1 billion in annual sales, strong future growth prospects through innovation and market expansion, and a significant opportunity to address unmet medical needs. As a category leader, our combined organization will bring value-driven innovations that can help healthcare providers advance patient outcomes, reduce procedure costs, enhance quality and evolve the treatment of urologic and pelvic conditions in ways that previously could not be realized by either company alone,” Boston Scientific eurology and pelvic health president Karen Prange said in a press release.

The deal is Boston Scientific’s largest acquisition since its infamous $27 billion buyout of Guidant Corp. nearly a decade ago. Boston Scientific also announced an investment and distribution deal with Preventice, a firm developing heart monitoring equipment, and Boston Scientific executives expressed interest in additional mergers and investments to spur growth.

“There are a lot of small technology companies out there continuing to do some innovative things that create value for the health care system, and so we continue to look at opportunities to expand,” said Prange.

About Boston Scientific
Boston Scientific transforms lives through innovative medical solutions that improve the health of patients around the world. As a global medical technology leader for more than 35 years, we advance science for life by providing a broad range of high performance solutions that address unmet patient needs and reduce the cost of healthcare.

For Further Information
More on the markets for urology devices can be found in this latest edition report published by iData entitled U.S. Market for Urological Devices, which covers the U.S. as a whole, as well as market segments for urinary incontinence devices, stone management devices, BPH treatment devices, urological endoscopes, prostate cancer treatment devices, urodynamic equipment, and nephrostomy devices.

The iData series on the market for urological devices also covers the U.S., India, China, Japan, and 15 countries in Europe. Full reports provide a comprehensive analysis including units sold, procedure numbers, market value, forecasts, as well as detailed competitive market shares and analysis of major players’ success strategies in each market and segment.

Register online or email us at [email protected] for an U.S. Market for Urological Devices report brochure and synopsis.

About Procedure Tracker
Procedure number data is available from iData’s Procedure Tracker service, which allows subscribers to define and analyze procedure data segmented by State, region, hospital, surgery centre, and physician. A customizable dashboard sorts procedure data for further analysis and research.

Explore our careers page for our current available job opportunities. This is your chance to join a fun and dynamic team in the medical market research industry. Send your resume to [email protected] with the job title in the subject line, and feel free to tell us a little about yourself. We look forward to hearing from you.

Like us on Facebook:
Follow us on LinkedIn:
Follow us on Twitter: